GLP-1 Science

Tirzepatide vs Semaglutide: Which GLP-1 Is Right for You?

Semaglutide activates one incretin receptor, GLP-1. Tirzepatide activates two, GIP and GLP-1, and in the only completed head-to-head weight management trial it produced greater average weight loss. Averages are not destiny: tolerance, availability, price at your dose, and your clinical history all move the individual answer.

Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 9 min read

Key facts

  • Semaglutide (in Wegovy® and Ozempic®) is a GLP-1 receptor agonist. Tirzepatide (in Zepbound® and Mounjaro®) activates both the GIP and GLP-1 receptors.
  • In SURMOUNT-5, the completed head-to-head trial, tirzepatide averaged about 20.2% body weight reduction at 72 weeks versus about 13.7% for semaglutide. Individual results vary and are not typical.
  • Side effect profiles are broadly similar: gastrointestinal symptoms concentrated around dose increases.
  • Published cohort data suggests patients who plateau on semaglutide can see additional average loss after a physician-managed switch to tirzepatide.
  • There is no fixed conversion chart between the two molecules; switching is a physician's re-titration decision.

What is the actual difference between the two molecules?

Both are once-weekly injectable peptides that mimic incretin hormones, the gut signals that regulate appetite and insulin. Semaglutide mimics one of them, GLP-1. Tirzepatide is engineered to activate two receptors at once, GLP-1 and GIP. The second pathway appears to add appetite and metabolic effects beyond GLP-1 alone, which is the mechanistic story behind the difference in trial averages.

Both molecules arrived through the same door: developed for type 2 diabetes, then approved for chronic weight management at dedicated doses. Both now carry additional indications, semaglutide in cardiovascular risk reduction and tirzepatide in obstructive sleep apnea, which occasionally matters for insurance coverage.

What did the head-to-head trial actually show?

For years the comparison leaned on separate trial programs, SURMOUNT for tirzepatide and STEP for semaglutide, with all the caveats cross-trial reading deserves. SURMOUNT-5 removed the caveats: a randomized trial of the two branded injectables at maximum tolerated doses in adults with obesity, without diabetes. At 72 weeks, tirzepatide averaged about 20.2% body weight reduction against about 13.7% for semaglutide, with a meaningfully larger share of tirzepatide participants reaching the deeper loss thresholds.

Those are averages from a study population, not predictions for you. Semaglutide remains a strongly effective medication by any historical standard, plenty of individuals respond better to it than the averages suggest, and response to either molecule spans a wide range. What the trial settles is only the population-level ranking at full doses.

Is one easier to tolerate than the other?

The side effect lists are near-identical: nausea, constipation, diarrhea, vomiting, fatigue, clustered around dose escalation and easing with time for most people. In SURMOUNT-5 the gastrointestinal event rates were broadly comparable between arms. Some clinicians observe anecdotally that the GIP component may soften nausea for some patients, but that remains an observation, not established comparative fact.

Individual tolerance is genuinely idiosyncratic. Some people who struggle on one molecule do better on the other, in both directions, and slowing the titration fixes more tolerance problems than switching does. That is a physician conversation, not a reason to assume the grass is greener.

3/mo CHROMA23+ Membership unlocks it at one clear price, medication priced separately and always shown.

Start the free assessment · Explore weight loss treatments

I plateaued on semaglutide. Is switching to tirzepatide worth it?

This is the question clinics hear most, and it now has data. Real-world cohort analyses of patients who switched from semaglutide to tirzepatide after a plateau report meaningful additional average weight loss in the months after the switch, on the order of several percent of body weight, though cohort data carries more noise than a randomized trial.

A plateau needs interpreting before it needs solving: a stall at a sub-maximal dose is a titration question, a stall after strong loss may be the medication doing exactly what maintenance looks like, and a stall with tolerability trouble reframes the whole plan. A physician sorts which one you have. The mechanics of moving between molecules, timing, dose mapping, expectations, are in our switching guide.

How do physicians actually choose between them?

A typical decision stacks five factors. Clinical history first: contraindications, gastrointestinal sensitivity, diabetes status, and the adjacent indications. Then goal magnitude: larger targets argue for the molecule with the stronger averages. Then access: what insurance covers, what the manufacturer programs cost at your likely doses, and what is realistically available month over month. Then format and availability constraints. Then price at dose, which diverges between the two more than starting prices suggest; the math is in our cost guide.

Notice what is not on the list: brand loyalty and internet averages. Two medications this effective make choosing the one you can access, afford, and tolerate for the long run more important than chasing the higher trial mean.

Frequently asked questions

Is semaglutide obsolete now?

No. It is a heavily studied, strongly effective medication with cardiovascular outcome data tirzepatide does not yet have, broad coverage, and an oral formulation. Population averages rank the molecules; they do not retire the runner-up.

Does CHROMA23® offer both?

CHROMA23® offers physician-prescribed treatment spanning branded semaglutide and tirzepatide products and, where a physician documents clinical appropriateness, compounded tirzepatide. It does not offer compounded semaglutide. What fits you is a physician determination after the free assessment.

Can I take them together?

No. They act on overlapping receptor systems and combining them has no approved or studied basis. Physicians choose one and optimize it.

Do the trial percentages apply to the compounded versions?

No. Trial data belongs to the branded products studied. Compounded preparations are not FDA-approved and have no trials of their own; the physician conversation should treat those as distinct facts. Individual results vary and are not typical.

About CHROMA23®

CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.

Sources

  1. SURMOUNT-5: tirzepatide vs semaglutide head-to-head (NEJM 2025)
  2. SURMOUNT-1: tirzepatide in adults with obesity (NEJM 2022)
  3. STEP 1: semaglutide 2.4 mg in adults with overweight or obesity (NEJM 2021)
  4. Barenbaum et al.: real-world outcomes in patients switched from semaglutide to tirzepatide (Obesity, 2026)
  5. University of Washington: tirzepatide vs semaglutide comparison summary

Keep reading

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.

All articles